Obesity Clinical Trial
Official title:
Economic Crisis and Adherence to the Mediterranean Diet: Possible Impact on Biomarkers of Inflammation and Metabolic Phenotypes in the Cohort of the MOLI-SANI Study
The socioeconomic gradient in health is well known and is partially explained by differences in health-related behaviours across socioeconomic groups. There is reason to believe that the current economic crisis has been contributing to the observed rapid decrease in the adherence to the Mediterranean diet, thus reducing a protective factor against the development of major chronic diseases. This project aims at investigating whether the economic crisis could account for the shifting from the Mediterranean diet. Additionally, it will address variations in inflammation biomarkers (possibly dietary-related) or metabolic phenotypes as useful biological accounts for the decline in the adherence to Mediterranean diet. This project will also test whether for economically weakest people cultural resources could somehow attenuate the impact of material circumstances on lifestyle changes attributable to the economic crisis.
Specific aims:
Aim 1: To identify population groups differently affected by the economic crisis within the
population-based cohort of the MOLI-SANI study recruited in the years 2005-2006 (before
economic crisis). This aim will be achieved by a new assessment of self-reported economic
difficulties possibly emerged after the recruitment.
Aim 2: To estimate possible changes in dietary and health-related behaviours (with particular
focus on the adherence to the Mediterranean diet) in subjects identified in the previous aim
as highly or poorly affected by the economic crisis. Inflammatory status and metabolic
phenotypes will be assessed in the two groups, recalled in a suitable proportion, to
establish a possible link between shifting from the Mediterranean diet and adverse health
outcomes. Quality of life and stress status will also be evaluated.
Aim 3: To evaluate in the group more affected by economic constraints whether nutrition
knowledge and mass media exposure would account for the decline in the adherence to the
Mediterranean diet and consequent changes in inflammatory status and/ or metabolic
phenotypes.
Experimental Design Aim 1: Aim 1 will identify two groups of subjects as being most or less
affected by the economic crisis. This aim will be reached by recall of 7,000 individuals from
the Moli-sani cohort recruited in the years 2005-2006. Subjects will be administered a
questionnaire to assess economic constraints likely occurred after the economic crisis onset.
The questionnaire will update socioeconomic position and estimate economic constraints, food
quality and food expenditure.
Experimental Design Aim 2: Within the two groups identified in aim 1, aim 2 will:
1. Perform a dietary follow up by administering the Italian version of the EPIC
questionnaire (9), already used at baseline, to estimate the changes in dietary habits.
Lifestyle follow up will be obtained by a validated questionnaire used at baseline.
2. Assess changes in inflammatory status by measurements of the following biomarkers:
High-sensitivity C-reactive protein, Interleukin-6, Interleukin-18, Tumor necrosis
factor, Plasminogen activator inhibitor-1, VCAM, ICAM, P-selectin, E-selectin,
L-selectin, CD40L, adiponectin, platelet and leukocyte counts, lipids, triglycerides,
glucose, insulin.
3. Estimate variations in the metabolic phenotypes (prevalence of hypertension, diabetes,
obesity, metabolic syndrome, and levels of blood pressure, hip and waist
circumferences).
Experimental Design Aim 3: A validated questionnaire on nutrition knowledge and exposure to
mass media will be administered. This will allow to retrospectively identify additional
subgroups differently exposed to information in order to estimate the role of cultural
resources in health-related behavioural changes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |